Compare Agnico Eagle Mines Ltd (AEM) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Bristol-Myers Squibb Co — how do they compare? Agnico Eagle Mines Ltd trades at $185.59 (market cap $92.01B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AEM | BMY | |
|---|---|---|
Market Cap | $92.01B | $129.94B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $65.89 |
52-Week Low | $130.23 | $42.60 |
Enterprise Value | $88.85B | $163.92B |
Dividend Yield | 0.99% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $185.82, up 2.96% on the day, reflecting strong momentum amid record gold prices and robust earnings. The stock exhibits a bullish technical setup with support near $180 and resistance at $186, while fundamentals are supported by a 37.5% net income margin and consistent earnings beats. Recent news highlights operational strength, with Q2 2026 EPS of $3.05 surpassing estimates and management projecting 20-30% production growth organically.
Outlook remains positive given analyst consensus and gold's uptrend, but rising unit costs and production challenges pose risks. With a $219.63 average price target implying 18% upside, AEM offers growth exposure to gold, though investors should monitor cost inflation and execution of expansion plans.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
